2 active not recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow R-DXd: new trials by email Literature Review of R-DXd trials Research Report on R-DXd
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830 - Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 110 | 2021-08-19 | 2026-06-01 |
| A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors DS-6000a - Renal Cell Carcinoma, Ovarian Tumor | Phase 1 | Active not recruiting | Daiichi Sankyo | 179 | 2020-12-22 | 2026-09-04 |
Carcinoma, Renal Cell (1) · Ovarian Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Small Cell Lung Carcinoma (1)
Daiichi Sankyo (1) · Merck Sharp & Dohme LLC (1)
United States (2) · Australia (1) · Austria (1) · Canada (1) · Hungary (1) · Israel (1) · Italy (1) · Japan (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · Switzerland (1)
2023 (1)